がんプロファイリングの世界市場レポート 2024年

がんプロファイリングの市場規模は近年急速に拡大しています。2023年の119億3,000万米ドルから2024年には134億米ドルへと、CAGR12.3％で成長します。がんプロファイリングに関する過去の期間に観察された成長は、がん罹患率の増加、精密医療アプローチの進歩と採用、バイオマーカーの臨床利用、標的療法につながる創薬の継続的な開発、医療界における患者や支持者の意識の高まりと支持活動など、いくつかの要因に起因しています。

2023年のがんプロファイリング市場で最大の地域は北米でした。がんプロファイリング市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 がんプロファイリング市場の特徴

第3章 がんプロファイリング市場の動向と戦略

第4章 がんプロファイリング市場- マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界のがんプロファイリング市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 がんプロファイリング市場セグメンテーション

• 世界のがんプロファイリング市場、技術別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 免疫学的検査
• PCR（重合連鎖反応）
• NGS（次世代シーケンシング）
• マイクロアレイ
• その場ハイブリダイゼーション
• 世界のがんプロファイリング市場、バイオマーカータイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• ゲノムバイオマーカー
• タンパク質バイオマーカー
• 世界のがんプロファイリング市場、がんタイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 乳がん
• 肺がん
• 結腸直腸がん
• 前立腺がん
• 黒色腫がん
• その他のがん
• 世界のがんプロファイリング市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 研究用途
• 臨床応用
• スクリーニング
• 診断
• 予後
• その他の用途

第7章 がんプロファイリング市場の地域および国分析

• 世界のがんプロファイリング市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界のがんプロファイリング市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋のがんプロファイリング市場

第9章 中国のがんプロファイリング市場

第10章 インドのがんプロファイリング市場

第11章 日本のがんプロファイリング市場

第12章 オーストラリアのがんプロファイリング市場

第13章 インドネシアのがんプロファイリング市場

第14章 韓国のがんプロファイリング市場

第15章 西欧のがんプロファイリング市場

第16章 英国のがんプロファイリング市場

第17章 ドイツのがんプロファイリング市場

第18章 フランスのがんプロファイリング市場

第19章 イタリアのがんプロファイリング市場

第20章 スペインのがんプロファイリング市場

第21章 東欧のがんプロファイリング市場

第22章 ロシアのがんプロファイリング市場

第23章 北米のがんプロファイリング市場

第24章 米国のがんプロファイリング市場

第25章 カナダのがんプロファイリング市場

第26章 南米がんプロファイリング市場

第27章 ブラジルのがんプロファイリング市場

第28章 中東のがんプロファイリング市場

第29章 アフリカのがんプロファイリング市場

第30章 がんプロファイリング市場の競合情勢と企業プロファイル

• がんプロファイリング市場の競合情勢
• がんプロファイリング市場の企業プロファイル
  • Illumina Inc.
  • Qiagen NV
  • NeoGenomics Inc.
  • Sysmex Corporation
  • HTG Molecular Diagnostics Inc.

第31章 世界のがんプロファイリング市場の競合ベンチマーキング

第32章 世界のがんプロファイリング市場の競争ダッシュボード

第33章 がんプロファイリング市場における主要な合併と買収

第34章 がんプロファイリング市場の将来展望と可能性分析

第35章 付録

“Cancer Profiling Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cancer profiling market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer profiling? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The cancer profiling market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Technology: Immunoassays; PCR (Polymerized Chain Reaction); NGS (Next-Generation Sequencing); Microarrays; In-Situ Hybridization
• 2) By Biomarker Type: Genomic Biomarkers; Protein Biomarkers
• 3) By Cancer Type: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Melanoma Cancer; Other Cancers
• 4) By Application: Research Applications; Clinical Applications; Screening; Diagnostics; Prognostics; Other Applications
• Companies Mentioned: Illumina Inc.; Qiagen NV; NeoGenomics Inc.; Sysmex Corporation; HTG Molecular Diagnostics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Cancer profiling refers to a diagnostic procedure aimed at analyzing the genetic information within tumor cells in the body. This process provides crucial insights into specific molecular or genetic alterations present in a tumor, such as gene mutations or other changes occurring in tumor DNA.

Key technologies involved in cancer profiling encompass immunoassays, PCR (polymerase chain reaction), NGS (next-generation sequencing), microarrays, and in-situ hybridization. Immunoassays represent laboratory tests designed to measure the concentration of specific proteins or other biomolecules found in blood or urine samples. Genomic biomarkers and protein biomarkers are utilized for profiling various cancers, including breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma cancer, and others. These profiling methods find applications in research, clinical diagnostics, screening, prognostics, and other healthcare-related purposes.

The cancer profiling market research report is one of a series of new reports from The Business Research Company that provides cancer profiling market statistics, including cancer profiling industry global market size, regional shares, competitors with a cancer profiling market share, detailed cancer profiling market segments, market trends, and opportunities, and any further data you may need to thrive in the cancer profiling industry. This cancer profiling market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cancer profiling market size has grown rapidly in recent years. It will grow from $11.93 billion in 2023 to $13.4 billion in 2024 at a compound annual growth rate (CAGR) of 12.3%. The growth observed in the historical period concerning cancer profiling can be attributed to several factors, including the increase in cancer incidence rates, the advancement and adoption of precision medicine approaches, the clinical utilization of biomarkers, ongoing developments in drug discovery leading to targeted therapies, as well as heightened awareness and advocacy efforts by patients and advocates within the medical community.

The cancer profiling market size is expected to see rapid growth in the next few years. It will grow to $20.35 billion in 2028 at a compound annual growth rate (CAGR) of 11.0%. Anticipated growth in the upcoming period in the field of cancer profiling can be associated with several key factors. These include the integration of artificial intelligence into diagnostic procedures, increased global collaborations in research efforts, broader applications of liquid biopsy techniques, supportive regulatory frameworks promoting precision medicine, and a growing emphasis on early detection strategies. Major trends expected in the forecast period encompass the dominance of liquid biopsy methods, the adoption of comprehensive genomic profiling techniques, the prominence of immunoprofiling methodologies, the establishment of collaborative data-sharing networks, and the utilization of single-cell sequencing approaches in cancer profiling and research.

The anticipated rise in the incidence of cancer is poised to drive the growth of the cancer profiling market in the coming years. Cancer incidence, representing the number of new cancer cases within a specific population during a defined period, is on the ascent due to factors such as urbanization, an expanding aging demographic, evolving lifestyles, and various environmental and genetic influences. The surge in cancer cases underscores the importance of cancer profiling, a process that identifies specific molecular or genetic alterations in tumors, aiding in the comprehensive understanding and treatment of cancer. In 2022, the American Cancer Society projected an estimated 1.9 million new cancer cases and 609,360 cancer-related deaths in the United States, highlighting the pressing need for advanced profiling techniques to address the increasing cancer burden.

The cancer profiling market is expected to benefit from the escalating funding dedicated to cancer research. Funding for cancer research involves financial support from diverse sources to conduct scientific investigations aimed at advancing knowledge, developing effective treatments, and discovering cures for various types of cancer. The application of cancer profiling facilitates targeted and personalized treatment approaches based on the unique molecular characteristics of individual cancers. Notably, in August 2023, the National Institute of Health (NCI) reported a total funding of $6.4 billion for the fiscal year 2021, reflecting a 1.6% increase from the previous fiscal year. This funding surge is indicative of the concerted efforts to advance cancer research, emphasizing the pivotal role of cancer profiling in shaping the future of cancer diagnosis and treatment.

A prominent trend in the cancer profiling market revolves around technological advancements, as major players strive to develop innovative technologies that fortify their market positions. Roche, a Switzerland-based multinational healthcare company, exemplifies this trend through the introduction of the AVENIO Edge System in December 2021. The AVENIO Edge System represents a significant leap in next-generation sequencing (NGS) technologies, offering an entirely automated solution for the sample preparation workflow in cancer profiling. This system spans DNA sample input to the production of sequencing-ready libraries, ensuring thorough testing, consistent results, and high-quality findings for precision medicine. The AVENIO Edge System stands as a testament to the ongoing commitment to technological innovation within the cancer profiling market.

Key players in the cancer profiling market are strategically focusing on the development of innovative in-vitro diagnostic test kits to optimize the treatment of advanced non-small cell lung cancer (NSCLC). In-vitro diagnostic test kits are specialized medical devices designed for the analysis of specimens, such as blood or tissue, outside the living organism (in vitro). One notable example is Qiagen, a leading Germany-based provider of sample and assay technologies. In May 2022, Qiagen launched the Thera screen EGFR Plus RGQ PCR Kit, an in-vitro diagnostic test specifically crafted for the sensitive analysis of EGFR mutations in non-small cell lung cancer (NSCLC) treatment. This real-time quantitative polymerase chain reaction (qPCR) test enhances detection limits, ensures faster turnaround times, and streamlines the process with automated sample extraction and results analysis. Notably, the kit now encompasses the detection of the C797S mutation, a crucial biomarker indicating resistance to third-generation EGFR tyrosine kinase inhibitors. This strategic development underscores the commitment of major industry players to advancing precision diagnostics in cancer treatment.

In August 2021, Illumina, a prominent US-based company specializing in DNA sequencing and genomic analysis, successfully completed the acquisition of GRAIL for an undisclosed sum. This strategic move is anticipated to expedite patient access to crucial multi-cancer early-detection tests, potentially leading to significant advancements in cancer diagnosis and treatment. GRAIL, the target of this acquisition, is a distinguished US-based healthcare company known for its expertise in the development of tests specifically designed for the early detection of various types of cancer.

Major companies operating in the cancer profiling market report are Illumina Inc., Qiagen NV, NeoGenomics Inc., Sysmex Corporation, HTG Molecular Diagnostics Inc., Caris Life Sciences, NanoString Technologies Inc., Guardant Health Inc., Foundation Medicine Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Genscript Biotech Corporation, Tempus Labs Inc., Hologic Inc., Predictive Oncology Inc., Abbott Laboratories, Agilent Technologies Inc., PerkinElmer Inc., Siemens Healthineers, Genomic Health Inc., Natera Inc., ArcherDX Inc., Personal Genome Diagnostics Inc., Enzo Biochem Inc., Cancer Genetics Inc., OncoDNA SA, Ribomed Biotechnologies Inc., Biocartis Group NV, N-of-One Inc., Cynvenio Biosystems Inc., Inivata Ltd., Burning Rock Biotech Limited, PathAI Inc., GENEWIZ Inc., Genoptix Inc., Oncomine Dx Target Test, OmniSeq Comprehensive, Resolution Bioscience, OncoCyte Corporation .

North America was the largest region in the cancer profiling market in 2023. The regions covered in the cancer profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the cancer profiling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cancer profiling market consists of revenues earned by entities by providing services such as surgery, chemotherapy, radiotherapy, hormonal therapy, and immunotherapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. Cancer profiling also includes sales of diagnostic tests and spectrometers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Cancer Profiling Market Characteristics

3. Cancer Profiling Market Trends And Strategies

4. Cancer Profiling Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On the Market
• 4.2. Ukraine-Russia War Impact On the Market
• 4.3. COVID-19 Impact On the Market

5. Global Cancer Profiling Market Size and Growth

• 5.1. Global Cancer Profiling Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Cancer Profiling Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Cancer Profiling Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Cancer Profiling Market Segmentation

• 6.1. Global Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Immunoassays
• PCR (Polymerized Chain Reaction)
• NGS (Next-Generation Sequencing)
• Microarrays
• In-Situ Hybridization
• 6.2. Global Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Genomic Biomarkers
• Protein Biomarkers
• 6.3. Global Cancer Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Melanoma Cancer
• Other Cancers
• 6.4. Global Cancer Profiling Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Research Applications
• Clinical Applications
• Screening
• Diagnostics
• Prognostics
• Other Applications

7. Cancer Profiling Market Regional And Country Analysis

• 7.1. Global Cancer Profiling Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Cancer Profiling Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Cancer Profiling Market

• 8.1. Asia-Pacific Cancer Profiling Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Cancer Profiling Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Cancer Profiling Market

• 9.1. China Cancer Profiling Market Overview
• 9.2. China Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Cancer Profiling Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Cancer Profiling Market

• 10.1. India Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Cancer Profiling Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Cancer Profiling Market

• 11.1. Japan Cancer Profiling Market Overview
• 11.2. Japan Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Cancer Profiling Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Cancer Profiling Market

• 12.1. Australia Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Cancer Profiling Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Cancer Profiling Market

• 13.1. Indonesia Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Cancer Profiling Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Cancer Profiling Market

• 14.1. South Korea Cancer Profiling Market Overview
• 14.2. South Korea Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Cancer Profiling Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Cancer Profiling Market

• 15.1. Western Europe Cancer Profiling Market Overview
• 15.2. Western Europe Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Cancer Profiling Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Cancer Profiling Market

• 16.1. UK Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Cancer Profiling Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Cancer Profiling Market

• 17.1. Germany Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Cancer Profiling Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Cancer Profiling Market

• 18.1. France Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Cancer Profiling Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Cancer Profiling Market

• 19.1. Italy Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Cancer Profiling Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Cancer Profiling Market

• 20.1. Spain Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Cancer Profiling Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Cancer Profiling Market

• 21.1. Eastern Europe Cancer Profiling Market Overview
• 21.2. Eastern Europe Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Cancer Profiling Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Cancer Profiling Market

• 22.1. Russia Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Cancer Profiling Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Cancer Profiling Market

• 23.1. North America Cancer Profiling Market Overview
• 23.2. North America Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Cancer Profiling Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Cancer Profiling Market

• 24.1. USA Cancer Profiling Market Overview
• 24.2. USA Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Cancer Profiling Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Cancer Profiling Market

• 25.1. Canada Cancer Profiling Market Overview
• 25.2. Canada Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Cancer Profiling Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Cancer Profiling Market

• 26.1. South America Cancer Profiling Market Overview
• 26.2. South America Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Cancer Profiling Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Cancer Profiling Market

• 27.1. Brazil Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Cancer Profiling Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Cancer Profiling Market

• 28.1. Middle East Cancer Profiling Market Overview
• 28.2. Middle East Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Cancer Profiling Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Cancer Profiling Market

• 29.1. Africa Cancer Profiling Market Overview
• 29.2. Africa Cancer Profiling Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Cancer Profiling Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Cancer Profiling Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Cancer Profiling Market Competitive Landscape And Company Profiles

• 30.1. Cancer Profiling Market Competitive Landscape
• 30.2. Cancer Profiling Market Company Profiles
  • 30.2.1. Illumina Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Qiagen NV
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. NeoGenomics Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Sysmex Corporation
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. HTG Molecular Diagnostics Inc.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Cancer Profiling Market Competitive Benchmarking

32. Global Cancer Profiling Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Cancer Profiling Market

34. Cancer Profiling Market Future Outlook and Potential Analysis

• 34.1 Cancer Profiling Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Cancer Profiling Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Cancer Profiling Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer